Patrick Johnson
General Practice · Belle Chasse, LANPI 1922307818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$316
- Lilly USA, LLC$274
- AbbVie$245
- Pfizer$231
- Novo Nordisk$191
- Boehringer Ingelheim$177
- plus $770 from 18 others
What the payments were for
- Food & beverage$2,204100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 13 | $316 |
| Lilly USA, LLC | 16 | $274 |
| AbbVie | 11 | $245 |
| Pfizer | 13 | $231 |
| Novo Nordisk | 11 | $191 |
| Boehringer Ingelheim | 11 | $177 |
| Medtronic | 1 | $144 |
| Gilead | 6 | $106 |
| Merck | 5 | $81 |
| Amgen | 4 | $71 |
| Exact Sciences | 3 | $55 |
| Organon | 2 | $44 |
| GSK | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Corium, LLC | 2 | $28 |
| Abbott | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Cranial Technologies, Inc | 1 | $21 |
| Alkermes, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- O-ARM-ST$144
How this compares
$2,204 in reported general payments places this provider in the 90th percentile of 1,221 general practice providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $95,110 |
| TrulicityDulaglutide | 85 | $92,618 |
| MounjaroTirzepatide | 50 | $82,448 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $69,829 |
| EliquisApixaban | 68 | $54,272 |
| OzempicSemaglutide | 35 | $50,895 |
| LinzessLinaclotide | 39 | $33,508 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $33,242 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $28,632 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,089 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $17,815 |
| Repatha SureclickEvolocumab | 31 | $17,430 |
| TradjentaLinagliptin | 14 | $17,347 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $16,487 |
| FarxigaDapagliflozin Propanediol | 22 | $13,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta | $177 | $210,919187 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $274 | $175,066135 claims |
| PfizerEliquis | $231 | $54,27268 claims |
| Novo NordiskOzempic | $191 | $50,89535 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere | $17 | $43,32871 claims |
| AbbVieLinzess | $245 | $33,50839 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $38 | $23,21949 claims |
| MerckJanumet Xr | $81 | $17,81521 claims |
| Johnson & JohnsonXarelto | $21 | $13,61517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 general practice providers in Louisiana.
Other general practice in Belle Chasse
- Ryan WolfeBelle Chasse$3K
- William CaldwellMetairie$943K
- William MaloneLafayette$46K
- Muhammad AnjumShreveport$33K
- Melissa RatliffBarksdale Afb$22K
- Louis PassauerMandeville$20K
- Stan Cowley JrMetairie$15K
- Justin TarverMonroe$11K
- Darrell BourgMarrero$10K
- Terry BillingsMetairie$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.